Contents ...
udn網路城邦
冠毒與疫苗一條龍服務讚或眨? 上次鴉片服務美國損失兩萬億美元
2022/04/19 14:12
瀏覽531
迴響0
推薦9
引用0

 冠毒與疫苗一條龍服務讚或眨?

上次服務美國損失兩萬億美元
1

_________________________________
1

[2020年事件 - 冠狀流行病毒案]

好樣的!

美國大財團藥廠大發利市!

默得納2021年營收成長結算22倍!

BNT2021年營收成長結算38倍

輝鋭2021年營收成長結算1.95倍(有其它藥物生產)

AZ2021年營收成長結算1.41倍

VIATRIS2021年營收成長結算1.66倍 (加拿大總理杜魯道家族有大量投資)

_________________________________

1

[1999年事件 - 普渡藥廠鴉片案]
1

美國猶太1999創辦的普渡藥廠(Purdue Pharma),以鴉片權充止痛劑出售。10年內到2009就已經造成,

45萬美國人因處方過量而死亡。


本案以公訴罰款80億美元結案,公司破產。負責人猶太家族  (Raymond Sackler) 面臨刑事訴訟,而集體訴訟等案件總求償金額高達兩萬億美元!


本事件2019年結案。而次年2020年冠毒就來了,收割韮菜族大一台一台接著演,

1

巧合嗎?

______________________

大浪淘沙,盤點超級流氓制藥公司。

2021年,以下反人類公司收入增加了最多:
Pfizer:95%
AstraZeneca: 41%
Moderna: 2200%
BioNTech: 3836% (Pfizer的新冠疫苗的實際外包公司)
Viatris:66% (包裹mrna物質的納米脂質體生產商,
加拿大小土豆家族重資投入)
Johnson & Johnson: 14%
其他沒搭上新冠疫苗地獄之車的醫藥公司的業績增
長都沒跑贏通脹。
今天你們笑的開心,小心以後拉清單,參考一下
前車之鑒普渡制藥。
【SOURCE: Comrade Napoleon】 報道
____________________________

【SOURCE: New York CNN Business

Purdue Pharma, the maker of OxyContin, has agreed to plead guilty to three federal criminal charges for its role in creating the nations opioid crisis and will pay more than $8 billion and close down the company.

The privately held company has agreed to pay a $3.5 billion fine
as well as forfeit an additional $2 billion in past profits, in addition
to the $2.8 billion it agreed to pay in civil liability. "Purdue Pharma actively thwarted the United States efforts to ensure compliance and prevent diversion, " said Drug Enforcement Administration Assistant Administrator Tim McDermott. "The devastating ripple effect of Purduesactions left lives lost and others addicted." The company doesnt have $8 billion in cash available to pay the fines. So Purdue will be dissolved as part of the settlement, and its assets will be used to create a new "public benefit company" controlled by a trust or similar entity designed for the benefit of the American public. The Justice Department said it will function entirely in the public interest rather than to maximize profits. Its future earnings will go to paying the fines
and penalties, which in turn will be used to combat the opioid crisis.
That new company will continue to produce painkillers such as OxyContin, as well as drugs to deal with opioid overdose. Deputy Attorney General Jeffrey Rosen, who announced the settlement, defended the plans for the new company to continue to sell that
drug,saying there are legitimate uses for painkillers such as OxyContin.
      The plan is for the company to make life-saving overdose rescue drugs and medically assisted treatment medications available at steep discounts to communities dealing with the opioid crisis. The Justice Department also reached a separate $225 million civil settlement with the former owners of Purdue Pharma, the Sackler family. Still, the Sackler family -- as well as other current and former employees and owners of the the company -- face the possibility that federal criminal charges will be filed against them. "Purdue deeply regrets and accepts responsibility for the misconduct detailed by the Department of Justice," said Purdue Chairman Steve Miller, who joined Purdues board in July 2018. "Purdue today is a very different company. We have made significant changes to our leadership, operations, governance,
      and oversight." Contributing to the opioid crisis The company, which filed for bankruptcy in 2019, pleaded guilty to violating federal anti-kickback laws, as it paid doctors ostensibly to write more opioid prescriptions.
      Abuse of prescription painkillers is a major cause of the nations opioid crisis. According to the Centers for Disease Control, 450,000 people died in the United States in the 10 years starting in 1999 from overdoses involving any opioid, including prescription and illicitopioids. And about a third of those deaths in 2018 involved prescription opioids.
      Although the more than $8 billion in fines and penalties in the agreement is a record to be paid by a pharmaceutical company, it is only a fraction of what it has cost federal, state and local governments to
      combat the opioid crisis. States across the country have filed claims topping $2 trillion in the Purdue Pharma bankruptcy case.
      States object to the deal
      So some states are objecting to the settlement. Twenty-five state attorneys general wrote to US Attorney General William Barr last week arguing against the plan to create a government-controlled company out of the assets of Purdue Pharma, arguing that the government should not be in the business of selling OxyContin.
      The letter said at least one potential buyer, which it did not identify, had already expressed interest in buying Purdue Pharmas drug business.
      "The public should be confident that public officials are seeking to avoid having special ties to an opioid company, conflicts of interest, or mixed motives in an industry that caused a national crisis, said the letter. "Selling the business to a private owner may also deliver more upfront money that cities and states can use to abate the opioid epidemic."
      Several state attorneys general who signed that earlier letter were quick to criticize the deal Wednesday. "This settlement provides a mere mirage of justice for the victims of Purdues callous misconduct," said
      Connecticut Attorney General William Tong. "The federal government had the power here to put the Sacklers in jail, and they didnt. Instead, they took fines and penalties that Purdue likely will never fully pay."
      The states are likely to continue to seek money from the company as part of its bankruptcy process. The settlement also needs the approval of the bankruptcy court for it to go into effect. "Every dollar paid here is one dollar less for states like Connecticut trying to maximize money
      from Purdue and the Sacklers to abate the opioid epidemic," said Tong. "Preserving Purdues ability to continue selling opioids as a public benefit
      corporation is simply unacceptable. The timing of this agreement mere weeks before the election raises serious questions about whether DOJ political leadership was negotiating in the best interest of
      the American public."
      Members of the Sackler family withdrew more than $10 billion from Purdue Pharma and put the money in family trusts as the company faced legal challenges related to its role in the nations opioid epidemic, according to court documents.
      But a spokesperson for the Sackler family defended those withdrawals, their actions with Purdue Pharma and their agreement with the DOJ.
      "Members of the Sackler family who served on Purdues board of directors acted ethically and lawfully, and the upcoming release of company documents will prove that fact in detail," said the
      familys statement. "This history of Purdue will also demonstrate that all financial distributions were proper."
      The statement said that familys ownership interest of Purdue Pharma had been valued at between $10 billion to $12 billion, and the loss of that stake was far more than the profits they took out of the company since the introduction of OxyContin.
      And they pointed out that despite the objections to the settlement, many state and city governments support the plan.
        "We have deep compassion for people who suffer from opioid addiction and abuse and hope the proposal will be implemented as swiftly as
        possible to help address their critical need."
        -- CNNs Melanie Schuman contributed to this report
        有誰推薦more

        限會員,要發表迴響,請先登入